|
Covaxin
Covaxin (codenamed as BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. As of October 2021, 110.6 million people in India have received Covaxin. On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use. As of 31 January 2022, Covaxin has been granted emergency use approval in 13 countries Medical uses Effectiveness A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. Effectiveness is generally expected to slowly decrease over time. Efficacy A phase 3 clinical trial with 25,798 participants found that the vaccine is effective against asymptomatic cases, effective against symptomatic disease, effective against severe disease, and effective against the Delta variant. Manufacturing As an inactivated vaccine, Covaxin uses a m ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
List Of COVID-19 Vaccine Authorizations
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi–GSK. Seven others are under assessment by the WHO: Sputnik V, Sinopharm WIBP, Abdala, Zifivax, Corbevax, COVIran Barekat, and SCB-2019. Of the 40 vaccines, 16 have a full or emergency authorization in only one country, 12 in ten or fewer countries, and 12 in more than ten countries. Note that in some countries, vaccines may be authorized solely for travel purposes. They may not be approved for the general population. For example, the CoronaVac, Covishield, BBIBP-CorV and Covaxin vaccines are not part of Australia's national vaccination program; however, they are recognized for the p ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Bharat Biotech
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in the city of Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products. Overview Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India. As of July 2020, the company has over 700 employees and has a presence worldwide. The company has been responsible for developing an eco-friendly recombinant and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC. They were one of the first to develop vaccines for viral diseases like Chikungunya and Zika. The company also produces vaccines for Japanese Encephalitis. Bharat Biotech has biosafety level 3 (BSL3) laboratories. COVID-19 vaccine development In April 2020, the company announced that they have partnered with US-based company FluGen and University of Wisconsin-Madison to develop ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Delta Variant
The Delta variant (B.1.617.2) was a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The Delta variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the Delta variant was becoming the dominant strain globally. It has mutations in the gene encoding the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus. In August 2021, Public Health England (PHE) reported secondary attack rate in household contacts of non-travel or unknown cases for Delta to be 10.8% ''vis-à-vis'' 10.2% for the Alpha variant; the case fatality rate for those 386,835 people with Delta is 0.3%, where 46% of the cases and 6% of the deaths are unvaccinated and below 50 yea ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
SARS-CoV-2 Delta Variant
The Delta variant (B.1.617.2) was a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The Delta variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the Delta variant was becoming the dominant strain globally. It has mutations in the gene encoding the SARS-CoV-2 coronavirus spike protein, spike protein causing the substitutions T478K, Variants of SARS-CoV-2#P681R, P681R and Variants of SARS-CoV-2#L452R, L452R, which are known to affect transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus. In August 2021, Public Health England (PHE) reported secondary attack rate in household contacts of non-travel or unknown cases for Delta to be 10.8% ''vis-à-vis'' 10.2% for the SARS-CoV-2 Alpha variant, Alpha variant; the case fatality rate for those ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Variants Of SARS-CoV-2
There are many variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Some are believed, or have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic. only the Omicron variant is designated as a circulating variant of concern by the World Health Organization. Overview The emergence of SARS-CoV-2 may have resulted from recombination events between a bat SARS-like coronavirus and a pangolin coronavirus through cross-species transmission. The earliest available SARS-CoV-2 viral genomes were collected from patients in December 2019, and Chinese researchers compared these early genomes with bat and pangolin coronavirus strains to estimate the ancestral human coronavirus type; the identified ancestral genome type ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
COVID-19 Vaccine
A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. In January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by March 2020, the global pharmaceutical industry announced a major commitment to address COVID19. In 2020, the first COVID19 vaccines were developed and made available to the public through emergency authorizations and conditional approvals. Initially, most COVID19 vaccines were two ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Inactivated Vaccine
An inactivated vaccine (or killed vaccine) is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive (but are almost always attenuated, that is, weakened). Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine. Inactivated vaccines were first developed in the late 1800s and early 1900s for cholera, plague, and typhoid. Today, inactivated vaccines exist for many pathogens, including influenza, polio (IPV), rabies, hepatitis A and pertussis. Because inactivated pathogens tend to produce a weaker response by the immune system than live pathogens, immunologic adjuvants and multiple "booster" injections may be required in some vaccines to provide an effective immune response against the pathogen. Attenuated vacci ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Inactivated Vaccine
An inactivated vaccine (or killed vaccine) is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive (but are almost always attenuated, that is, weakened). Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine. Inactivated vaccines were first developed in the late 1800s and early 1900s for cholera, plague, and typhoid. Today, inactivated vaccines exist for many pathogens, including influenza, polio (IPV), rabies, hepatitis A and pertussis. Because inactivated pathogens tend to produce a weaker response by the immune system than live pathogens, immunologic adjuvants and multiple "booster" injections may be required in some vaccines to provide an effective immune response against the pathogen. Attenuated vacci ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Vero Cell
Vero cells are a lineage of cells used in cell cultures. The 'Vero' lineage was isolated from kidney epithelial cells extracted from an African green monkey (''Chlorocebus'' sp.; formerly called ''Cercopithecus aethiops'', this group of monkeys has been split into several different species). The lineage was developed on 27 March 1962, by Yasumura and Kawakita at the Chiba University in Chiba, Japan. The original cell line was named '' Vero'' after an abbreviation of , which means 'green kidney' in Esperanto, while itself means 'truth' in Esperanto. Characteristics The Vero cell lineage is continuous and aneuploid, meaning that it has an abnormal number of chromosomes. A continuous cell lineage can be replicated through many cycles of division and not become senescent. Vero cells are interferon-deficient; unlike normal mammalian cells, they do not secrete interferon alpha or beta when infected by viruses. However, they still have the Interferon-alpha/beta receptor, so they ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Beta-propiolactone
β-Propiolactone is an organic compound of the lactone family, with a four-membered ring. It is a colorless liquid with a slightly sweet odor, highly soluble in water and miscible with ethanol, acetone, diethyl ether and chloroform.''Merck Index'', 12th Edition, entry 8005. The word propiolactone usually refers to this compound, although it may also refer to α-propiolactone. Production β-Propiolactone is prepared industrially by the reaction of formaldehyde and ethenone in the presence of aluminium- or zinc chloride as catalyst: In the research laboratory, propiolactones have been produced by the carbonylation of epoxides. Reactions and applications It reacts with many nucleophiles in a ring-opening reactions. With water hydrolysis occurs to produce 3-hydroxypropionic acid (hydracryclic acid). Ammonia gives the β-alanine, which is a commercial process. Propiolactone was once widely produced as an intermediate in the production of acrylic acid and its esters. That app ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Immunologic Adjuvant
In immunology, an adjuvant is a substance that increases or modulates the immune response to a vaccine. The word "adjuvant" comes from the Latin word ''adiuvare'', meaning to help or aid. "An immunologic adjuvant is defined as any substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens." In the early days of vaccine manufacture, significant variations in the efficacy of different batches of the same vaccine were correctly assumed to be caused by contamination of the reaction vessels. However, it was soon found that more scrupulous cleaning actually seemed to ''reduce'' the effectiveness of the vaccines, and some contaminants actually enhanced the immune response. There are many known adjuvants in widespread use, including aluminium salts, oils and virosomes. Overview Adjuvants in immunology are often used to modify or augment the effects of a vaccine by stimulating the immune system to re ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Novavax
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. Their vaccine, Nuvaxovid, was approved in the European Union at the end of 2021 and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. History In June 2013, Novavax acquired the Matrix-M adjuvant platform with the purchase of Swedish company Isconova AB and renamed its new subsidiary Novavax AB. ResVax In March 2015, the company completed a Phase I trial for its Ebola vaccine candidate, as well as a phase II study in adults for its RSV vaccine, which wo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpg "Click for more on -> COVID-19 Vaccine")
